A Study of CLN-619 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors

NCT05117476 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

440

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumor
NSCLC

Interventions

DRUG: CLN-619
DRUG: Pembrolizumab
DRUG: Paclitaxel
DRUG: Carboplatin AUC 6
DRUG: pemetrexed
DRUG: Datopotamab deruxtecan-dlnk (Dato-DXd)

Sponsor

Cullinan Therapeutics Inc.